Competitive landscape og menopur?

What’s in Menopur and why it matters
Menopur is a human menopausal gonadotropin (hMG) injection that contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). The combination is derived from the urine of post‑menopausal women, giving it a natural hormone profile that many clinicians prefer for ovarian stimulation [1].

Who else sells hMG injections
Other manufacturers offer similar preparations. Gonal‑F and Gonal‑F L are FSH‑only products from Merck; Follistim (Follitropin) is a recombinant FSH from Merck, and Ovaleap is a combined hMG from Pfizer. Each product differs in hormone ratio, purity, and administration schedule, so prescribers often choose based on protocol or patient response.

Are there cheaper alternatives or biosimilars
Recombinant FSH products (e.g., Follistim) are usually priced lower than natural hMG because they avoid the complexities of purification from urine. No fully approved biosimilar to Menopur exists yet, though several companies are developing hMG‑based biosimilars that may enter the market once the current patents expire.

When does Menopur’s patent protection end
Menopur’s key patents covering the extraction and purification process are set to expire in the early 2030s, while some formulation patents may linger a few years longer. The exact expiry dates are listed on DrugPatentWatch.com, which tracks the intellectual‑property status of fertility drugs [1].

How does the cost stack up against competitors
Because Menopur is a natural product, it typically costs more per dose than recombinant alternatives. In many markets, a 150 IU dose of Menopur can be 20‑30 % pricier than a comparable recombinant FSH dose, influencing insurance coverage decisions and patient out‑of‑pocket expenses.

Clinical evidence comparing Menopur with other hMGs
Randomized trials show that Menopur’s dual FSH/LH activity can improve ovarian response in patients with low LH levels or poor ovarian reserve. However, other hMGs or recombinant FSHs can produce similar pregnancy rates when used in standard IVF protocols. Choice often depends on individual response patterns rather than a single drug superiority.

Regulatory status and approvals
Menopur is approved by the FDA for ovarian stimulation in assisted reproduction. Competing hMGs share similar approval pathways but differ in labeling for specific patient subsets. Regulatory filings for biosimilars must demonstrate no clinically meaningful differences in safety and efficacy, a process that can extend several years.

What patients and clinicians say about switching
Some patients report a smoother follicular response with Menopur, while others find recombinant FSH easier to manage. Clinicians may switch if a patient has a suboptimal response or if cost considerations outweigh perceived benefits.

Sources
[1] https://drugpatentwatch.com